Lung LesionsMediastinal and Hilar Lymph Node Enlargement
Investigational drug(s) / intervention(s)
Contrast-enhanced endobronchial ultrasound
Contrast-enhanced endobronchial ultrasound: Using CE-EBUS to observe pulmonary lesions and abnormal enlarged intrathoracic lymph nodes, the enhancement characteristics of benign and malignant lesions under CE-EBUS were extracted for both conditions.
Study summary
Exploring the Clinical Application Value of Contrast Enhancement Features in CE-EBUS Images for the Diagnosis of Pulmonary Lesions and Intrapulmonary Lymph Nodes
Eligibility
Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria:
* Age \>18 years old；
* Enlargement of at least one intrathoracic LN (short diameter \> 1 cm) or central parenchymal lung lesions adjacent to the airway detected on chest CT, or increased fluorodeoxyglucose uptake in at least one intrathoracic lymph node on PET / CT (standardized uptake value \> 2.5)；
* CP-EBUS-TBNA is required to determine the diagnosis or staging, the patient agreed to undergo CE-EBUS, and there were no contraindications to EBUS-TBNA;
* Patients who have good compliance and sign informed consent.
Exclusion Criteria:
* Patients with known hypersensitivity to ultrasound contrast components;
* Patients with severe pulmonary hypertension (pulmonary artery pressure \> 90 mmHg);
* Patients with angina pectoris, acute coronary syndrome, clinically unstable ischemic heart disease, heart failure, cardiac dysfunction, and cardiac disease with right-to-left shunting;
* Patients with uncontrolled essential hypertension and adults with respiratory distress syndrome;
* Pregnant or lactating women；
* Patients with contraindications to bronchoscopy；
* Patients with other conditions that, in the opinion of the investigator, make the patient unsuitable for the study.
Primary outcome measure(s)
Diagnostic accuracy of CE-EBUS in the differential diagnosis of benign and malignant intrathoracic lymphadenopathy — 6 month post-procedure Diagnostic accuracy is defined as the number of lesions correctly identified as malignant or benign divided by the total number of lesions using CE-EBUS interpretation criteria.
Diagnostic accuracy of CE-EBUS in the differential diagnosis of benign and malignant intrapulmonary lesions — 6 month post-procedure Diagnostic accuracy was defined as the number of lesions correctly identified as malignant or benign divided by the total number of lesions using the CE-EBUS interpretation criteria.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.